UNSPSC 51343816: Lamivudine/tenofovir DF

This classification denotes a combination drug for treatment of HIV. The first component, LAMIVUDINE, has US FDA Unique Ingredient Identifier of 2T8Q726O95. The second component, TENOFOVIR DISOPROXIL FUMARATE, has US FDA Unique Ingredient Identifier of OTT9J7900I.

UNSPSC 51343816 Lamivudine/tenofovir DF, a Commodity code, does not map to any relevant state and local procurement activity in the recent opportunities block. The code nominates a specific antiretroviral pharmaceutical combination, yet the recent solicitations tagged under this code span mobile EMS dosing applications, long-term care pharmacy services, aquatic center operations, procurement conferences, pharmacy benefits networks, naloxone distribution, forensic drug standards, and on-call maintenance contracting — none of which involve lamivudine or tenofovir-based HIV treatments or antiretroviral procurement. The mismatch suggests either miscoding at the issuing-body level or a fundamental disconnect between the UNSPSC category definition and current state and local purchasing patterns. The single opportunity that addresses pharmaceutical services — Dane County's RFP for Badger Prairie Health Care Center pharmacy services (due October 22, 2026) — requires comprehensive drug and supply distribution and dispensing but does not specify antiretroviral formularies or lamivudine/tenofovir procurement.

State and local jurisdictions do procure HIV treatments and antiretrovirals through pharmacy benefits programs, group purchasing organizations (GPOs), and long-term care pharmacy service contracts, but those procurement records do not appear under this UNSPSC code in the current dataset. If lamivudine/tenofovir-based products are being purchased by state or local bodies, they are either coded differently at the source or are embedded within broader pharmaceutical service contracts that do not itemize individual drug lines in public summaries. Vendors targeting state and local HIV treatment supply chains should verify coding practices with issuing bodies directly and monitor GPO and pharmacy-benefit RFP activity rather than rely on this code as a primary discovery signal.